ROR2 Antibody (HX07): sc-80329
- ROR2 Antibody (HX07) is a mouse monoclonal IgG1, cited in 3 publications, provided at 100 µg/ml
- raised against an extracellular domain of ROR2 of human origin
- recommended for detection of ROR2 of human origin by WB; non cross-reactive with ROR1
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for ROR2 Antibody (HX07). This work is in progress.
QUICK LINKS
SEE ALSO...
ROR2 Antibody (HX07) is a mouse monoclonal IgG1 antibody that detects ROR2 in human samples through western blotting (WB). ROR2, also known as neurotrophic tyrosine kinase receptor-related 2, is a single-pass transmembrane tyrosine-protein kinase receptor that plays a crucial role in skeletal and endocrine development. ROR2 is primarily located in the cell membrane, where ROR2′s presence is vital for mediating signaling pathways that influence the differentiation of osteoblasts and the early formation of chondrocytes. ROR2′s proper localization is essential for function, as ROR2 interacts with various signaling molecules, including canonical Wnt1 and Wnt3, to regulate their pathways effectively. Additionally, ROR2 contains several important structural domains, such as a cytoplasmic tyrosine kinase domain and an extracellular immunoglobulin-like domain, which are critical for activity and interactions. Defects in ROR2 can lead to significant skeletal disorders, including brachydactyly type B1 and Robinow syndrome, highlighting ROR2′s importance in maintaining skeletal integrity and function. Anti-ROR2 antibody (HX07) is an invaluable tool for researchers studying these pathways and their implications in human health.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
ROR2 Antibody (HX07) References:
- Ror2 as a therapeutic target in cancer. | Debebe, Z. and Rathmell, WK. 2015. Pharmacol Ther. 150: 143-8. PMID: 25614331
- ROR2 blockade as a therapy for osteoarthritis. | Thorup, AS., et al. 2020. Sci Transl Med. 12: PMID: 32938794
- WNT5a Signaling through ROR2 Activates the Hippo Pathway to Suppress YAP1 Activity and Tumor Growth. | Wang, K., et al. 2023. Cancer Res. 83: 1016-1030. PMID: 36622276
- ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer. | Tabrizian, N., et al. 2023. Cell Rep. 42: 112937. PMID: 37552603
- Cancer-associated fibroblasts influence Wnt/PCP signaling in gastric cancer cells by cytoneme-based dissemination of ROR2. | Rogers, S., et al. 2023. Proc Natl Acad Sci U S A. 120: e2217612120. PMID: 37722040
- ROR2 homodimerization is sufficient to activate a neuronal Wnt/calcium signaling pathway. | Riquelme, R., et al. 2023. J Biol Chem. 299: 105350. PMID: 37832874
- ROR2/Wnt5a Signaling Regulates Directional Cell Migration and Early Tumor Cell Invasion in Ovarian Cancer. | Grither, WR., et al. 2024. Mol Cancer Res. 22: 495-507. PMID: 38334461
- Structure and function of the ROR2 cysteine-rich domain in vertebrate noncanonical WNT5A signaling. | Griffiths, SC., et al. 2024. Elife. 13: PMID: 38780011
- ROR2 Regulates Cellular Plasticity in Pancreatic Neoplasia and Adenocarcinoma. | Benitz, S., et al. 2024. Cancer Discov. 14: 2162-2182. PMID: 38975886
- ROR2 promotes cell cycle progression and cell proliferation through the PI3K/AKT signaling pathway in gastric cancer. | Liu, Q., et al. 2024. Mol Carcinog. 63: 2316-2331. PMID: 39150155
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ROR2 Antibody (HX07) | sc-80329 | 100 µg/ml | $322.00 |